Literature DB >> 8204360

Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19.

L T Mantovani1, S Miotti, S Ménard, S Canevari, F Raspagliesi, C Bottini, F Bottero, M I Colnaghi.   

Abstract

Folate-binding proteins (FBP), which are molecules relevant in folate metabolism, are overexpressed in ovarian carcinomas, as detected by the monoclonal antibodies (MAb) MOv18 and MOv19, which recognise two different epitopes of the gp38/FBP. In this paper, features of the FBP such as the distribution on normal tissues and the release in biological fluids of normal and tumour origin have been investigated. Immunohistochemical analyses on frozen sections of normal tissues showed the presence of the gp38/FBP on some epithelia. The reactivity of both the MAb on Fallopian tubes was intense and comparable to that observed on ovary carcinoma sections. The kidney, bronchial glands, alveolar epithelium of the lung, oesophagus, stomach, pancreas, breast and thyroid showed different levels of staining. By MOv18/MOv19 double-determinant immunoradiometric assay (DDIRMA), the gp38/FBP was found in soluble form in ascitic fluid, serum and urine of nude mice in which the human ovary carcinoma cell line IGROV1 grew as ascitic carcinomatosis. In human biological fluids, the gp38/FBP was detected in ascites of 60% of ovarian carcinoma patients, and in 29% of those with other carcinomas, but not in patients with non-epithelial tumours or with other non-tumoral pathologies. The mean serum arbitrary units (a.u.)/ml values of ovary carcinoma patients were significantly different to those of healthy donors or patients with endometriosis (P < 0.005 and P < 0.01, respectively), but not when compared to the sera of lung carcinoma patients. In addition, the sensitivity of DDIRMA was poor, since only 24% of the ovary carcinoma patients were positive with this assay. When a restricted number of cases selected for the presence of tumour cells in the ascites was examined, the percentage of DDIRMA-positive sera and ascites rose to 41 and 94%, respectively. In the urine, a strong reactivity was observed in the samples of both normal and tumour origin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204360     DOI: 10.1016/0959-8049(94)90257-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

1.  A folic acid-based functionalized surface for biosensor systems.

Authors:  Kaustubh D Bhalerao; Stephen C Lee; Winston O Soboyejo; Alfred B O Soboyejo
Journal:  J Mater Sci Mater Med       Date:  2007-01       Impact factor: 3.896

Review 2.  Immunotherapy for ovarian cancer.

Authors:  Justin M Drerup; Yang Liu; Alvaro S Padron; Kruthi Murthy; Vincent Hurez; Bin Zhang; Tyler J Curiel
Journal:  Curr Treat Options Oncol       Date:  2015-01

3.  Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors:  Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

4.  Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response.

Authors:  Yu-Li Chen; Ming-Cheng Chang; Chia-Yen Huang; Ying-Cheng Chiang; Han-Wei Lin; Chi-An Chen; Chang-Yao Hsieh; Wen-Fang Cheng
Journal:  Mol Oncol       Date:  2011-12-20       Impact factor: 6.603

5.  A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.

Authors:  Michael H Kershaw; Jennifer A Westwood; Linda L Parker; Gang Wang; Zelig Eshhar; Sharon A Mavroukakis; Donald E White; John R Wunderlich; Silvana Canevari; Linda Rogers-Freezer; Clara C Chen; James C Yang; Steven A Rosenberg; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

6.  Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.

Authors:  Quaovi H Sodji; James R Kornacki; John F McDonald; Milan Mrksich; Adegboyega K Oyelere
Journal:  Eur J Med Chem       Date:  2015-04-08       Impact factor: 6.514

7.  Standardization and Optimization of Intraoperative Molecular Imaging for Identifying Primary Pulmonary Adenocarcinomas.

Authors:  Jarrod D Predina; Olugbenga Okusanya; Andrew D Newton; Philip Low; Sunil Singhal
Journal:  Mol Imaging Biol       Date:  2018-02       Impact factor: 3.488

Review 8.  Farletuzumab in lung cancer.

Authors:  Anish Thomas; Julia Maltzman; Raffit Hassan
Journal:  Lung Cancer       Date:  2013-01-26       Impact factor: 5.705

9.  The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.

Authors:  J E Nutt; A R A Razak; K O'Toole; F Black; A E Quinn; A H Calvert; E R Plummer; J Lunec
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

10.  Functional folate receptor alpha is elevated in the blood of ovarian cancer patients.

Authors:  Eati Basal; Guiti Z Eghbali-Fatourechi; Kimberly R Kalli; Lynn C Hartmann; Karin M Goodman; Ellen L Goode; Barton A Kamen; Philip S Low; Keith L Knutson
Journal:  PLoS One       Date:  2009-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.